Praktikertjänst-backed oncology company Aprea has received a $5.7m series C extension adding to an initial $56.8m close in November 2018 that featured Karolinska Development.
Aprea Therapeutics, a Sweden-based oncological drug developer backed by healthcare provider Praktikertjänst, has increased its series C round to €55m ($62.8m) after securing a $5.7m contribution from unspecified funds managed by Janus Henderson Investors.
The extension follows an initial $56.8m close announced in November 2018 that was led by Redmile Group with participation from the university’s investment arm, Karolinska Development.
Rock Springs Capital, 5AM Ventures, Versant Ventures, Health Cap and Sectoral Asset Management also backed the initial series C…